iOmx is a young, dynamic start-up in the field of immuno-oncology located in Martinsried/Munich, Germany. Backed by a powerful technology platform and internationally renowned investors, iOmx is driving forward a cutting-edge portfolio of early-stage novel immune-checkpoint drugs through pre-clinical and clinical development.
Imprint: https://iomx.com/imprint
Imprint: https://iomx.com/imprint
Location: Germany, Bavaria, Martinsried
Employees: 11-50
Total raised: $148.92M
Founded date: 2016
Investors 2
| Date | Name | Website |
| 26.12.2021 | MIG AG | mig.ag |
| 08.11.2022 | M Ventures | m-ventures... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.12.2021 | Series B | $73.56M | - |
| 05.10.2021 | Series B | $75.36M | - |
Mentions in press and media 5
| Date | Title | Description |
| 11.12.2021 | iOmx Therapeutics raises EUR 65 million in Series B round | Martinsried / Munich, Germany, 5 October, 2021: iOmx Therapeutics AG (iOmx), a biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, today announced the closing of a Series B round tot... |
| 09.10.2021 | Top 10 Healthcare Startups in Germany | The global healthcare market is expected to reach USD 11,908.9 billion by 2022, growing at a CAGR of 8.9%. Germany stands as the 3rd largest market for healthcare and medical products and is No. 1 in Europe, and the country’s healthcare ind... |
| 06.10.2021 | iOmx raises 65 million euros | Martinsried-based iOmx Therapeutics AG has closed a 65 million euros Series B financing round. The financing was led by Athos Service GmbH - the family office of the Strüngmann family - and MIG Capital AG, with participation from existing i... |
| 05.10.2021 | iOmx Therapeutics Raises EUR 65M in Series B Funding | iOmx Therapeutics AG, a Martinsried / Munich, Germany-based biopharmaceutical company developing cancer therapeutics based on next generation immune checkpoint targets, closed a Series B round totaling EUR 65m. The round was co-led by Athos... |
| 30.09.2019 | iOmx Therapeutics announces discovery of novel, druggable immune-checkpoint targets | iOmx Therapeutics announced today the presentation of two posters at the Fifth International Cancer lmmunotherapy Conference (CICON 2019) which showcases the company’s proprietary, high-throughput genetic screening platform, iOTarg™. iOTarg... |